In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF has resulted in consistent 25%-26% relative risk reduction of the primary endpoint of cardiovascular death or hospitalization for heart failure.
SGLT2 inhibitors have also been shown to slow the progression of renal function decline. In trials of empagliflozin and dapagliflozin, no patients without diabetes developed ketoacidosis, although SGLT2 inhibitors do increase the risk for diabetic ketoacidosis in patients with diabetes and other high-risk conditions.
Learn more about the treatment of HFrEF.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Alanna Morris. Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization - Medscape - Sep 09, 2021.